ValuEngine lowered shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a report published on Thursday.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Celsion from a buy rating to a hold rating in a research report on Thursday, January 11th. Oppenheimer assumed coverage on shares of Celsion in a research report on Tuesday, November 21st. They issued an outperform rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Celsion has an average rating of Buy and a consensus target price of $11.90.
Celsion (NASDAQ CLSN) opened at $2.58 on Thursday. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06.
An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC acquired a new stake in Celsion Co. (NASDAQ:CLSN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned 0.24% of Celsion at the end of the most recent reporting period. 3.84% of the stock is owned by institutional investors and hedge funds.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.